Last reviewed · How we verify
Ticlopidine and itraconazole — Competitive Intelligence Brief
marketed
Antiplatelet agent + Antifungal agent
ADP receptor (P2Y12) for ticlopidine; Fungal CYP51 for itraconazole
Cardiovascular / Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Ticlopidine and itraconazole (Ticlopidine and itraconazole) — Turku University Hospital. This is a combination of ticlopidine (a platelet aggregation inhibitor) and itraconazole (an antifungal agent), used together to manage thrombotic and fungal complications.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ticlopidine and itraconazole TARGET | Ticlopidine and itraconazole | Turku University Hospital | marketed | Antiplatelet agent + Antifungal agent | ADP receptor (P2Y12) for ticlopidine; Fungal CYP51 for itraconazole |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antiplatelet agent + Antifungal agent class)
- Turku University Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ticlopidine and itraconazole CI watch — RSS
- Ticlopidine and itraconazole CI watch — Atom
- Ticlopidine and itraconazole CI watch — JSON
- Ticlopidine and itraconazole alone — RSS
- Whole Antiplatelet agent + Antifungal agent class — RSS
Cite this brief
Drug Landscape (2026). Ticlopidine and itraconazole — Competitive Intelligence Brief. https://druglandscape.com/ci/ticlopidine-and-itraconazole. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab